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Abstract
Objectives: Asthma trials suggest that patients reaching total disease control have an optimal Health Related Quality of Life
(HRQoL). Moreover, rhinitis is present in almost 80% of asthmatics and impacts asthma control and patient HRQoL. We
explored whether optimal HRQoL was reachable in a real-life setting, and evaluated the disease and patient related patterns
associated to optimal HRQoL achievement.
Methods and Findings: Asthma and rhinitis HRQoL, illness perception, mood profiles, rhinitis symptoms and asthma control
were assessed by means of validated tools in patients classified according to GINA and ARIA guidelines. Optimal HRQoL,
identified by a Rhinasthma Global Summary (GS) score #20 (score ranging from 0 to 100, where 100 represents the worst
possible HRQoL), was reached by 78/209 (37.32%). With the exception of age, no associations were found between clinical
and demographic characteristics and optimal HRQoL achievement. Patients reaching an optimal HRQoL differed in disease
perception and mood compared to those not reaching an optimal HRQoL. Asthma control was significantly associated with
optimal HRQoL (x
2=49.599; p,0.001) and well-controlled and totally controlled patients significantly differed in achieving
optimal HRQoL (x
2=7.617; p,0.006).
Conclusion: Approximately one third of the patients in our survey were found to have an optimal HRQoL. While
unsatisfactory disease control was the primary reason why the remainder failed to attain optimal HRQoL, it is clear that
illness perception and mood also played parts. Therefore, therapeutic plans should be directed not only toward achieving
the best possible clinical control of asthma and comorbid rhinitis, but also to incorporating individualized elements
according to patient-related characteristics.
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Introduction
The goal of asthma treatment is to reach the good symptom
control and to prevent disease worsening [1], leading to an
improvement of Patient-Reported Outcomes (PROs). Among
these, Health-Related Quality of Life (HRQoL) is a widely used
outcome to assess patients’ perspective [2].
Clinical trials have demonstrated that total asthma control is an
achievable target at all disease stages [3,4], and that HRQoL
correlates with the level of disease control [5]. Furthermore, when
treatment is tailored to achieve total control, the vast majority of
asthma patients (regardless of the severity of asthma) have the
possibility of reaching HRQoL scores approaching the maximum,
with little or no impact of the disease on patient’s life [6].
Results from the above trials refer to asthma patients studied in
the framework of controlled clinic trials and the study design did
not take comorbid rhinitis into account. Observational studies
indicated that patients suffering from symptomatic rhinitis were
less likely to attain good asthma control and emphasised that the
presence of rhinitis symptoms influenced not only the quality of life
related to the upper airways but also to lower airways and the
global HRQoL score [7–11]. Up to now, the possibility of patients
with asthma and comorbid rhinitis to reach an optimal HRQoL in
real life has not been explored. We speculated that this goal is
achievable and that it could be associated to a different disease
experience. Reaching an optimal HRQoL, from patient’s
perspective, means to minimize or even to cancel the impact of
the disease on daily life. To date this aspect has not been
evaluated. We speculated that when optimal HRQoL is achieved,
patients’ generate new cognitive representations of, and emotional
reactions to, their illness. In other words, if the HRQoL is
minimum, the disease could be considered [12].
The aims of our cross-sectional study were: to assess the level of
quality of life related to asthma and rhinitis in an adult population
in order to evaluate whether optimal HRQoL was achievable in a
real-life setting; to investigate the clinical and demographic pattern
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patients reaching optimal HRQoL differ in terms of illness
perception and stress levels from those who do not; to investigate
whether among the patients with controlled asthma, those
reaching an optimal HRQoL differ in illness perception and
stress levels.
Materials and Methods
Patients
Asthma and rhinitis patients scheduled for a follow-up visit to
the Allergy and Respiratory Departments of six Italian medical
centers were recruited over a two-month period starting in
November 2009. The descriptive observational study was
approved by the Ethics Committee of the Azienda Ospedaliero-
Universitaria San Martino di Genova and written informed
consent was obtained from each patient prior to the beginning of
the study.
Inclusion criteria for the study were: adult age (18–75 years),
comprehension of spoken and written Italian, availability to
participate in the study (informed consent signature), and a history
of diagnosed allergic asthma with concomitant rhinitis [13,14].
Exclusion criteria were: presence of impaired cognitive functions,
visual-auditory deficits, and clinical conditions incompatible with
questionnaire completion.
While the patients were waiting for their follow-up visit, they
were invited to complete the required questionnaires (see below).
During the visit, the ARIA guidelines were used to establish the
patient’s rhinitis status [13]. Taking into account the patients were
classified according to GINA guidelines [14]. For the current
study, the patient’s level of control (ACT score [15]) and
therapeutic strategy were recorded.
Questionnaires
The Asthma Control Test (ACT) [15,16] permits the determi-
nation of the level of asthma control. This questionnaire consists of
five items that investigate the presence, in the preceding four
weeks, of limitations at work or school due to asthma, the presence
of diurnal and nocturnal symptoms, and the use of rescue
medications. One item concerns the subjective perception of the
level of asthma control. Patients assigned scores of 1–5 to each
item, resulting in the following grading system: uncontrolled
asthma, scores 5–19; well controlled asthma, scores 20–24; total
disease control, score of 25.
Rhinitis symptoms were assessed using the Total 5 Symptoms
Score (T5SS) that includes the following symptoms: nasal
discharge (rhinorrhea), nasal congestion, itchy nose, sneezing,
and itching eyes. All symptoms were graded using a score from
0 (absent) to 3 (very troublesome), with total scores ranging from
0–15.
The RHINASTHMA is the only questionnaire that allows the
evaluation of the impact of concomitant rhinitis and asthma on
patient HRQoL [17]. RHINASTHMA is composed of 30 items;
the analysis provides individual scores for upper airways, lower
airways, respiratory allergy impact, and a composite score, the
Global Summary (GS), which indicates the overall impact of the
disease. Patients use a five-point Likert scale (not at all, a little,
fairly, much, very much) to indicate the extent to which they were
bothered by each problem during the two weeks preceding the
completion of the questionnaire. These responses were then
converted into scores from 0 to 100, with higher scores
corresponding to worse HRQoL. Similar to previous studies in
which optimal HRQoL was defined as Asthma Quality of life
(AQLQ) score of 80% or higher [6], a RHINASTHMA GS score
from 0 to 20, indicating minimal or absent disease impact on
patient life, was considered reflective of optimal HRQoL.
The Illness Perception Questionnaire (IPQ-R) is a widely-used
questionnaire that assesses patient beliefs and understanding of the
illness [18]. The ‘‘identify factor’’ section asks the patient about the
presence of symptoms (pain, sore throat, nausea, fatigue, weight
loss, stiff joints, sore eyes, breathlessness, headache, upset stomach,
sleep disturbances, dizziness, and loss of strength) and whether the
patient believes that each selected symptom is related to asthma/
rhinitis. The ‘‘identity factor’’ score is calculated as the sum of the
scores for these symptoms. A five-point Likert scale (1=strongly
disagree, 5=strongly agree) is employed in the second section of
the IPQ-R, which investigates the following disease-related
symptoms: consequences, timeline acute/chronic, timeline cycli-
cal, coherence, personal control, treatment control, and emotional
representation. The factors are calculated as the sum of the item
scores.
The Profile of Mood States (POMS) is a well-established, factor-
derived measure of psychological distress [19]. The test consists of
58 adjectives to which patients respond on a five-point scale
(0=not at all to 4=extremely), providing a global index of stress
and six factorial scores: Tension-Anxiety, Depression-Dejection,
Anger-Hostility, Vigor-Activity, Fatigue-Inertia, and Confusion-
Bewilderment. The scores for each scale were normalized to a
mean of 50 and a standard deviation of 10.
Statistical analysis
Patients were included in the statistical analysis on the basis of
completeness of clinical data and completion of .90% in the PRO
questionnaires. Data are presented in percentage for demographic
characteristics and clinical data, as mean 6 standard deviation for
continuous variables investigated. Exploratory analysis of demo-
graphic and clinical data was performed using the following
procedures. Pairwise associations between categorical variables
were assessed through the chi-squared test for heterogeneity.
Student’s t-test was used to detect significant differences in the
means of quantitative variables for independent samples. Spear-
man’s rho was used to assess the relationships between variables or
rank scores. Discriminant power of the POMS total score on
optimal HRQoL was assessed through receiver operating
characteristic (ROC) analysis. To estimate the association of each
IPQ-R factor with RHINASTHMA GS scores, a linear regression
model was applied (statistical significance: a=0.05).
Results
Out of 238 patients initially recruited for the study, 227 agreed
to fill in the questionnaires. Eighteen patients were excluded from
the analysis due to clinical data incompleteness or missing
questionnaire answers (.10%), leaving 209 patients (mean age
45.14616.75 years) in the final analysis group (Table 1). ACT and
T5SS mean scores showed far-from-ideal asthma and rhinitis
control (Table 2). HRQoL was also impaired, reaching only 70%
of the best score.
Optimal HRQoL, identified by Rhinasthma Global Summary
(GS) score #20, was reached by 78/209 (37.32%) (Table 3).
Clinical characteristics were compared between patients who had
or had not achieved optimal HRQoL; no significant differences
were found concerning gender, education, and smoking habits,
while younger patients had a better HRQoL (p,0.05). Optimal
HRQoL achievement was not associated with rhinitis duration
(intermittent vs persistent; x
2=1.753; p,0.229), rhinitis degree of
severity (mild/moderate vs severe; x
2=0.142; p,0.737) and
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x
2=3.430; p,0.088).
Patients with an optimal GS score showed significantly lower
T5SS score (p,0.001) and higher ACT score (p,0.001)
compared to those with a GS score higher than 20. ACT score,
categorized into uncontrolled (,20) and controlled ($20) scores,
was significantly associated with GS optimal score achievement
(x
2=49.599; p,0.001). Patients achieving optimal HRQoL
showed median ACT and T5SS values greater than patients not
reaching optimal HRQoL (Figures 1A–B). Considering only
controlled patients, the level of ACT score (25 vs 20–24) is
associated to the achievement of the optimal HRQoL: a
significantly higher percentage of totally controlled patients
compared to well controlled ones (84% vs 51%) reached the
optimal HRQoL (x
2=7.617; p,0.006).
Table 2. Asthma and rhinitis related quality of life, rhinitis
symptoms and level of control expressed as minimal, maximal
and mean scores in observed population (n=209).
Minimum Maximum Mean Std. Deviation
RHINASTHMA UA 0 100.00 31.6025 23.54
RHINASTHMA LA 0 84.62 30.5953 21.77
RHINASTHMA RAI 0 87.50 25.7852 20.27
RHINASTHMA GS 0 83.33 29.6147 18.56
T5SS TOT 0 15 7.01 4.04
ACT TOT 5 25 18.44 5.33
Legend: UA=Upper Airways; LA=Lower Airways; RAI=Respiratory Allergy
Impact; GS=Global Score; T5SS=Total 5 Symptoms Score; ACT=Asthma
Control Test. doi:10.1371/journal.pone.0031178.t002
Table 3. RHINASTHMA, T5SS and ACT scores (mean and
standard deviations) in patients who achieved or not an
optimal HRQoL (Student’s t-test; m6sd).
Patients with
GS score #20
(N=78)
Patients with
GS score .20
(N=131)
Mean Std. Deviation Mean Std. Deviation
RHINASTHMA UA 26.38 9.72 41.41 9.72
RHINASTHMA LA 19.97 7.53 43.21 18.29
RHINASTHMA RAI 10.10 7.64 35.90 19.44
RHINASTHMA GS 12.36 5.03 40.74 15.31
T5SS TOT 4.75 3.27 8.30 3.86
ACT TOT 21.98 3.79 16.20 5.07
Legend: UA=Upper Airways; LA=Lower Airways; RAI=Respiratory Allergy
Impact; GS=Global Score; T5SS=Total 5 Symptoms Score; ACT=Asthma
Control Test. doi:10.1371/journal.pone.0031178.t003
Figure 1. Asthma control and rhinitis symptoms score in
patients who had or had not achieved optimal asthma and
rhinitis related quality of life (NN-HRQoL). ACT=asthma control
test; T5SS=Total 5 symptoms score; GS=global summary. GS score
,20 is expression of an optimal asthma and rhinitis related quality of
life. In order to describe the ACT (panel A) and T5SS (panel B) variable
trend as regards to RHINASTHMA Global Score, a pyramid population
graphic was used. Green bars identify patients with GS score .20; blue
bars identity patients with GS score ,20.
doi:10.1371/journal.pone.0031178.g001
Table 1. Demographic characteristics and clinical data for the
209 patients in the final analysis group.
DEMOGRAPHIC CHARACTERISTICS
Sex Male 36.5%
Female 63.5%
Smoking Smoker 16.5%
Non-smoker 72.9%
Former smoker 9.6%
Education Primary school 9.3%
Secondary school 19.5%
High school 47.8%
Academic degree 23.4%
CLINICAL DATA
Rhinitis Intermittent
Persistent
51.8%
48.2%
Mild
Moderate to severe
51.9%
48.1%
Asthma GINA Classification in therapy 1
2
3
4
5
22.7%
29.5%
36.9%
9.7%
1%
doi:10.1371/journal.pone.0031178.t001
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optimal HRQoL reported more symptoms and ascribed more of
them to asthma and rhinitis (Table 4), and showed significantly
higher identity, illness consequences, timeline acute/chronic -
cyclical, and emotional representation scores than patients who
achieved optimal HRQoL (Table 5). Linear regression of the IPQ-
R scores indicated that identity is the most relevant factor in
predicting the RHINASTHMA GS score (Test F=57.46;
p,0.001).
Regarding profiles of mood state, patients who achieved optimal
HRQoL reported significantly lower scores in all POMS factors
except for Vigor-Activity (Table 5). ROC analysis indicated that
the probability for patients to achieve optimal HRQoL was 67%
with a cut-off score for POMS of 187.5 (Area under the Curve -
AUC=0.715, sensitivity 69%).
A sub-analysis including the 86 patients with well and totally
controlled asthma (ACT score between 20 and 25) was performed.
Controlled patients showed significant differences in illness
perception and profile of mood states based on whether patients
had achieved optimal HRQoL (Table 6).
Discussion
The goals of this observational real-life study were to verify
whether the clinical-trial HRQoL results were achievable in a real-
life setting also considering the burden of comorbid rhinitis, and to
explore which disease- and patient-related factors were associated
with this achievement. Our study shows that optimal HRQoL is
an achievable target but is rarely achieved in real life in patients
suffering from allergic asthma with comorbid rhinitis.
With the exception of age, the patient demographic character-
istics were not associated with the achievement of optimal
HRQoL; indeed, our results are in line with previous findings
indicating a reduced HRQoL in older subjects [20,21]. Possible
explanations for this finding include the longer duration of
symptoms in older persons and the way they face their disease
Optimal HRQoL achievement was independent of the degree of
severity of asthma and rhinitis, an observation in agreement with
Table 4. Illness perception in patients reaching near-normal HRQoL (GS score ,20) and not reaching an optimal HRQoL (GS $20).
(Student’s t-test; m6sd).
IPQ-R Symptom Presence of the symptom Relation between the symptom and asthma/rhinitis
GS #20
(N=78)
GS .20
(N=131) P
GS #20
N=78)
GS .20
(N=131) P
Pain 0.1760.38 0.2860.45 0.08 0.1360.33 0.2360.42 0.07
Sore Throat 0.2960.46 0.4760.50 0.02* 0.1960.40 0.3860.49 0.01*
Nausea 0.0860.28 0.1660.36 0.15 0.0160.12 0.1060.31 0.02*
Breathlessness 0.7560.43 0.8560.36 0.10 0.7360.45 0.8160.39 0.17
Weight Loss 0.0460.20 0.1260.33 0.06 0.0460.20 0.1060.31 0.13
Fatigue 0.5860.50 0.7960.41 0.00* 0.4460.50 0.6360.48 0.01*
Stiff Joints 0.0860.28 0.3360.47 0.00* 0.0460.20 0.1960.39 0.00*
Sore Eyes 0.6760.47 0.7160.45 0.51 0.6460.48 0.6760.47 0.64
Wheeziness 0.8260.38 0.9260.27 0.03* 0.7860.41 0.8560.35 0.21
Headache 0.3260.47 0.5460.50 0.00* 0.2260.42 0.4060.49 0.01*
Upset Stomach 0.1860.39 0.3860.49 0.00* 0.0760.26 0.2960.91 ,0.001*
Sleep Disturbances 0.3360.47 0.6960.46 0.00* 0.2660.44 0.5660.50 ,0.001*
Dizziness 0.1460.35 0.3660.48 0.00* 0.1060.30 0.2860.45 ,0.001*
Loss Of Strength 0.4760.50 0.7460.44 0.00* 0.3360.47 0.6060.49 ,0.001*
Legend: IPQ-R=Illness perception Questionnaire Revised version; GS=Global Summary.
*Level of significance p,0.05.
doi:10.1371/journal.pone.0031178.t004
Table 5. Illness perception (IPQ-R) and profile of mood state
(POMS) in patients reaching an optimal HRQoL (GS score #20)
and not reaching an optimal HRQoL (GS .20). (Student’s
t-test; m6sd).
IPQ-R factors
GS #20
(N=78)
GS .20
(N=131) P value
Identity 3.9262.46 5.8763.09 ,0.001*
Timeline Acute/Chronic 18.6165.80 19.9464.75 ,0.001*
Consequences 12.7464.84 16.1764.85 ,0.001*
Personal Control 19.0765.31 19.0764.21 1.00
Treatment Control 17.1364.18 17.0062.96 0.80
Illness Coherence 15.6864.22 14.6963.92 0.10
Timeline Cyclical 10.8464.12 12.7963.63 ,0.001*
Emotional Representation 11.7865.58 15.5666.11 ,0.001*
POMS factors
Tension-Anxiety 45.8568.12 54.94612.67 0.001*
Depression-Dejection 47.2967.02 53.83612.14 0.001*
Anger-Hostility 47.6167.55 55.19613.64 0.001*
Vigor-Activity 51.9069.99 50.30611.08 0.350
Fatigue-Inertia 46.9767.33 56.27612.31 0.001*
Confusion-Bewilderment 43.5868.09 51.81611.30 0.001*
POMS TOT 179.40637.74 221.74660.85 0.001*
Legend: IPQ-R=Illness perception Questionnaire Revised version; GS=Global
Summary.
*Level of significance p,0.05.
doi:10.1371/journal.pone.0031178.t005
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[3,11] our results confirm that, in asthma rhinitis patients observed
in real life, totally controlled patients were more likely to reach
optimal HRQoL, and patients were able to distinguish between
well and total control in terms of HRQoL [3].
Patients reaching an optimal HRQoL differed in disease
perception and mood (Tables 4, 5 and 6). They enjoy a clearer
vision of the symptomatological characteristics of the illness and
awareness of its temporal evolution, attributing fewer negative life
consequences and fewer unpleasant emotions to the disease. The
association between illness perception and HRQoL can lead to
two different outcomes. On one hand, reaching a optimal HRQoL
can result in a better vision of the disease itself, with the patient
perceiving the disease as more integrated in daily life and less
burdensome. On the other hand, disease perception itself
contributes to its impact on life. In fact, the number of symptoms
that patient ascribes to respiratory allergy (identity factor) is the
strongest IPQ-R correlate of HRQoL (RHINASTHMA GS
score).
Therefore, investigating which symptoms and disturbances
patient associates with their disease, providing a correct education,
helping them to recognize the symptomatological characteristics of
asthma and rhinitis and to distinguish them from symptoms
related to other pathologies, seems a necessary step in order to
reach and maintain optimal HRQoL levels. Patients attaining
optimal HRQoL reported lower levels of tension, depression,
aggressiveness, tiredness, and confusion (Table 5). If the patients’
HRQoL was not bothersome, the presence of the disease would
not influence their mood, although patients with a better mood
profile could possess more psychological resources to cope with
their disease. The outcomes measures that describe patients’
subjective viewpoint are increasingly emphasized as an essential
indicator in asthma [12,23].
Asthma treatment has been shown to greatly highly improve
HRQoL and reduce the burden of asthma [1,2]; moreover, total
control of asthma is an achievable goal that patients perceive in
terms of quality of life. However, real-life surveys indicated that
rhinitis symptoms, detectable in most asthmatics, were often
underestimated, and asthma control was often not reached
[10,11]. In our study, the level of control was significantly
associated with HRQL; moreover, well-controlled and totally
controlled patients significantly differed in achieving optimal
HRQoL. Among controlled patients, those who reach an optimal
HRQoL ascribe less symptoms to the disease, reporting less
consequences of asthma and rhinitis in their life and showing a
better mood profile. Our results should be evaluated in the light of
study’s strengths and limits. The main strength is that data
collection was conducted in real life, providing relevant data for
clinical management of asthma and comorbid rhinitis. Several
limitations should be taken into account. First of all the small
number of patients enrolled in the study and second, cross
sectional nature of the analysis does not allow for drawing causal
inferences of the determinants of optimal HRQoL. Third, due to
the study design, we were unable to control for the confounding
effects such as prescribed drugs, treatment adherence, and
presence of physical or psychiatric diseases.
Although clinical trials have demonstrated that asthmatic
patients may reach an optimal HRQoL, which implies minimal
or absent disease impact on patient life, this possibility had not
been explored yet in a real-life setting. The present study
demonstrates that, although the majority of real-life patients with
both asthma and rhinitis did not achieve optimal HRQoL, this is
an achievable target. Failure to reach optimal HRQoL is related
neither to disease severity nor to demographic characteristics
(apart from age). Optimal HRQoL is related to asthma control
and rhinitis symptoms and a significantly higher percentage of
totally controlled patients reached an optimal HRQoL level. This
evidence, confirming the results of clinical trials [4,6], could be
useful in targeting treatment goals in clinical practice. Impaired
HRQoL may be an unnecessary hardship in some patients that
may be avoided by aiming for best-achievable control of both
asthma and rhinitis. This objective may be reached through a
treatment plan tailored according to both disease and patient-
related factors. Further research using longitudinal design with
larger sample sizes are required to better explore the causal
relationship between optimal HRQoL achievement and patient
and disease related factors.
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Table 6. Patient reported outcomes (PROs) differences in
patients with controlled asthma (ACT $20) (N=86) achieving
or not an optimal HRQoL. (Student’s t-test; m6sd).
IPQ-R factors
GS #20
(N=51)
GS .20
(N=35) P value
Identity 3.8062.458 5.5762.515 0.003*
Timeline Acute/Chronic 19.6264.802 20.1063.933 0.645
Consequences 12.4264.348 14.9763.567 0.008*
Personal Control 19.8264.715 19.4063.013 0.664
Treatment Control 17.6063.580 17.2362.800 0.633
Illness Coherence 16.5663.308 16.1062.905 0.531
Timeline Cyclical 10.9863.473 11.6363.662 0.427
Emotional
Representation
11.6664.684 13.4565.650 0.126
POMS factors
Tension-Anxiety 45.0968.479 54.63611.943 0.001*
Depression-Dejection 46.8866.470 52.85611.292 0.006*
Anger-Hostility 46.8666.151 54.41613.582 0.002*
Vigor-Activity 52.7469.587 54.15610.582 0.569
Fatigue-Inertia 47.2167.117 55.11611.318 0.001*
Confusion-
Bewilderment
43.0567.329 50.67611.156 0.001*
POMS TOT 176.35634.474 213.52661.296 0.002*
Legend: IPQ-R=Illness perception Questionnaire Revised; POMS=Profile of
Mood States Questionnaire. GS=global summary. A GS score ,20 is expression
of an optimal asthma and rhinitis related quality of life.
*Level of significance
p,0.05.
doi:10.1371/journal.pone.0031178.t006
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